The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide ...